Allena Pharmaceuticals is a biopharmaceutical company that focuses on developing and distributing innovative oral enzyme therapeutics to treat a range of rare and severe metabolic and kidney disorders. The company's lead product candidate is reloxaliase, a first-of-its-kind oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by high urinary oxalate levels commonly associated with kidney stones and other serious kidney disorders. The therapeutic is in its late-stage development and, if approved, will provide a much-needed solution for a currently unmet medical need.